<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Regadenoson (REG) is a A2a receptor selective pharmacologic SPECT imaging agent </plain></SENT>
<SENT sid="1" pm="."><plain>Its safety in unselected <z:hpo ids='HP_0006510'>chronic obstructive pulmonary disease</z:hpo> (COPD) or <z:hpo ids='HP_0002099'>asthma</z:hpo> (AM) undergoing SPECT imaging has not been well evaluated </plain></SENT>
<SENT sid="2" pm="."><plain>We retrospectively identified 228 patients (COPD n = 126 and AM n = 102, Grp 1) undergoing REG SPECT from Jan to Nov 2009 and compared to 1,142 patients without COPD and AM (control, Grp 2) </plain></SENT>
<SENT sid="3" pm="."><plain>A standard 400 Î¼g REG bolus was used and gated Tc-99 m tetrofosmin SPECT done </plain></SENT>
<SENT sid="4" pm="."><plain>Patient demographics, REG SPECT data, side effects, <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> occurrences, and any exacerbation of COPD or AM leading to treatment, hospitalization or <z:hpo ids='HP_0011420'>death</z:hpo> were evaluated </plain></SENT>
<SENT sid="5" pm="."><plain>The side effect profile of Grp 1 was also compared to a historical cohort who underwent intravenous <z:chebi fb="0" ids="4653">dipyridamole</z:chebi> <z:chebi fb="0" ids="37804">thallium-201</z:chebi> imaging and <z:chebi fb="3" ids="16335">adenosine</z:chebi> SPECT </plain></SENT>
<SENT sid="6" pm="."><plain>Both groups were comparable with regards to baseline characteristics </plain></SENT>
<SENT sid="7" pm="."><plain>There was 0% incidence of clinical exacerbation of COPD or AM after REG </plain></SENT>
<SENT sid="8" pm="."><plain>COPD patients had more non-significant <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> (58.3% vs. Grp 2, 43%, P = 0.004) </plain></SENT>
<SENT sid="9" pm="."><plain>There was 0% incidence of any atrio-ventricular block and only 2 instances of brief <z:hpo ids='HP_0004755'>supraventricular tachycardia</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>When compared to the historical cohort of COPD who underwent IV <z:chebi fb="0" ids="4653">dipyridamole</z:chebi> <z:chebi fb="80" ids="30440">thallium</z:chebi> imaging, COPD in Grp 1, had more <z:hpo ids='HP_0002094'>dyspnea</z:hpo> and flushing and when compared to COPD/AM patients who underwent <z:chebi fb="3" ids="16335">adenosine</z:chebi> SPECT, Grp 1 pts had more of flushing and <z:hpo ids='HP_0002315'>headache</z:hpo> (24.9% vs. 2.8%, P = &lt;0.001) but less of <z:e sem="disease" ids="C0006266" disease_type="Disease or Syndrome" abbrv="">bronchospasm</z:e> (1.3% vs. 6.9%, P = 0.022) and <z:mp ids='MP_0010519'>AV block</z:mp> (0% vs. 4.2%, P = 0.014) </plain></SENT>
<SENT sid="11" pm="."><plain>REG SPECT can be safely performed in COPD and AM population </plain></SENT>
</text></document>